Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 1,305,873
- Estimated value
- $16,271,178
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By F2 Vision SCS
Morana Jovan-Embiricos
Insider Reports History
- Reporting-owner location
- Boston, MA
- Latest reporting-owner signature
-
/s/ Brett Hagen, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Morana Jovan-Embiricos
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 1,136,525
- Estimated value
- $14,161,102
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By Globeways Holdings Ltd.
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 16,674,766
- Estimated value
- $13,211,417
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Shares held by ElevateBio LLC
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 622,175
- Estimated value
- $7,752,301
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By F2-TPO Investments, LLC
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 537,392
- Estimated value
- $6,695,904
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By F2 Bioscience I 2017 Ltd.
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 325,333
- Estimated value
- $4,053,649
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By F2 MG Ltd.
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 4,193,874
- Estimated value
- $3,322,806
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- F2 Capital I 2020 LLC
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 214,798
- Estimated value
- $2,676,383
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By F2 MC, LLC
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 207,803
- Estimated value
- $2,589,225
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- Direct
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 2,059,884
- Estimated value
- $1,632,046
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- F2 MG Ltd.
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 2,038,583
- Estimated value
- $1,615,169
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Shares held by F2 MC, LLC
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 104,762
- Estimated value
- $1,305,335
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By F2 GC, LLC
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Common Stock
- Shares / value
- 71,599
- Estimated value
- $892,124
- Report date
- 24 Jun 2022
- Price
- $12.46
- Ownership
- By F2 Bio TD, LLC
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 867,678
- Estimated value
- $687,461
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- F2 Bioscience AV 2022 LLC
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 668,072
- Estimated value
- $529,313
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Shares held by F2 TPO Investments, LLC
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 100,197
- Estimated value
- $79,386
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Direct
Form 4 holding
Director
Kalaris Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 9,000
- Estimated value
- Report date
- 03 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Cullinan Oncology, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 24 Jun 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Morana Jovan-Embiricos
4
KLRS
Kalaris Therapeutics, Inc.
- Report period
- 03 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Jun 2026, 16:38
- Role
- Director
- Next action
- Open filing details
4
KLRS
Kalaris Therapeutics, Inc.
- Report period
- 10 Apr 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Apr 2025, 17:08
- Role
- Director
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 06 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 16:05
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 11 May 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 May 2023, 17:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 28 Jul 2022
- Transactions
- 6
- Transaction value
- +$37,581,859
- Accepted by SEC
- 01 Aug 2022, 16:35
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CGEM
Cullinan Oncology, Inc.
- Report period
- 24 Jun 2022
- Transactions
- 5
- Transaction value
- +$13.78
- Accepted by SEC
- 28 Jun 2022, 21:24
- Role
- 10%+ Owner
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 17 May 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 May 2022, 16:28
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 10 Nov 2021
- Transactions
- 2
- Transaction value
- -$19,812
- Accepted by SEC
- 15 Nov 2021, 16:17
- Role
- Director
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 05 Nov 2021
- Transactions
- 4
- Transaction value
- -$302,455
- Accepted by SEC
- 09 Nov 2021, 17:43
- Role
- Director
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 27 Oct 2021
- Transactions
- 2
- Transaction value
- -$54,510
- Accepted by SEC
- 29 Oct 2021, 17:02
- Role
- Director
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 21 Oct 2021
- Transactions
- 6
- Transaction value
- -$337,045
- Accepted by SEC
- 25 Oct 2021, 18:24
- Role
- Director
- Next action
- Open filing details
4
CGEM
Cullinan Oncology, Inc.
- Report period
- 16 Sep 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 25 Mar 2022, 19:32
- Role
- Director
- Next action
- Open filing details
4
KLRS
Allovir, Inc.
- Report period
- 25 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 27 May 2021, 16:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details